Alector company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

alector.com

Founded Year

2013

Stage

IPO | IPO

Total Raised

$194.5M

Date of IPO

2/7/2019

Market Cap

0.71B

Stock Price

8.62

About Alector

Alector is a neurology-focused startup that is focused on the discovery and development of immuno-modulatory therapies for Alzheimer's disease and other neurodegenerative disorders. The company is combining antibody technology and recent discoveries in neuro-immunology and human genetics to develop a platform of therapeutics that harness the immune system to fight dementia and neurodegeneration.

Alector Headquarter Location

131 Oyster Blvd Suite 600

South San Francisco, California, 94080,

United States

415-231-5660

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Alector

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alector is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Alector Patents

Alector has filed 15 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/24/2019

5/3/2022

Clusters of differentiation, Immunology, Immune system, Transcription factors, G protein coupled receptors

Grant

Application Date

5/24/2019

Grant Date

5/3/2022

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Transcription factors, G protein coupled receptors

Status

Grant

Latest Alector News

11:30 EDT Vascular Dementia Market Is Contemplated to Surge at a CAGR of 4.05% in the 7MM for the Study Period of 2019-2032, Est...

Apr 7, 2022

News provided by Share this article Share this article The increase in the Vascular Dementia market size is a direct consequence of expected approval of emerging therapies, entrance of major players, and increasing patient population of Vascular Dementia in the 7MM countries. LAS VEGAS, April 7, 2022 /PRNewswire/ -- DelveInsight's Vascular Dementia Market Insights  report proffers a detailed comprehension of Vascular Dementia market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Vascular Dementia market size from 2019 to 2032 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan). The Vascular Dementia market size in the 7MM was valued at USD 2,230 million in 2021 and is anticipated to grow at a CAGR of 4.05% for the study period (2019-2032). Key pharmaceutical Vascular Dementia companies such as Charsire Biotechnology Corp, ProNeurogen, Cyclerion Therapeutics, Pfizer, Acadia pharmaceuticals, Resverlogix Corp, Pinteon Therapeutics, Aribio and others are reported to bring a significant shift in the Vascular Dementia market. The Vascular Dementia emerging therapies that are expected to launch in the forecast period include BAC (also called CSTC1, CHARSIRE Trauma Complex 1), PNA1, Apabetalone, CY6463, AR1001, PNA5, and others. The United States has the highest percentage of Vascular Dementia patient population. Whereas Japan has consistently shown the second-highest patient population among the 7MM countries. Among the EU5, Germany has the largest  Vascular Dementia patient population. The overall Vascular Dementia market is expected to boost due to the rising prevalence of cases over the globe and thus the surge in treatment options. Along with these, the expected launch of emerging therapies will boost the Vascular Dementia treatment market in the forecasted period. For further information on market impact by therapies, download the Vascular Dementia market sample at Vascular Dementia Therapeutic Scenario Vascular Dementia Overview The word dementia describes a set of symptoms that can include memory loss and difficulties with thinking, problem-solving, or language. In Vascular Dementia, these symptoms occur when the brain is damaged because of problems with blood supply to the brain. Vascular Dementia (VaD) is an etiological category of dementia characterized by severe cognitive impairment resulting from ischemic or hemorrhagic stroke or hypoperfusion affecting brain regions important for memory, cognition, and behavior. Vascular Dementia symptoms can begin gradually or can occur suddenly and then progress over time, with possible short periods of improvement. Vascular Dementia diagnosis should be suspected in patients with significant Vascular Dementia risk factors such as stroke, or heart disease who exhibit abrupt changes in cognition. Vascular Dementia Epidemiology Segmentation As per the assessment of DelveInsight, the total prevalent Dementia cases in the 7MM were found to be 21,591,565 in 2021, which are expected to increase at a Compound Annual Growth Rate (CAGR) of 2.42% during the study period. As per DelveInsight's estimates, 7MM accounts for 2,795,390 diagnosed prevalent Vascular Dementia cases in 2021, which are expected to increase at a CAGR of 3.60%. The Vascular Dementia Market  report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into Prevalent Cases of Dementia Diagnosed Prevalent Cases of Vascular Dementia Age-specific Diagnosed Prevalent Cases of Vascular Dementia Keen to learn how Vascular Dementia Epidemiological Trends are going to appear in 2032 for the 7 MM, Download @ Vascular Dementia Epidemiological Insights Vascular Dementia decreases blood flow to the brain which damages several brain tissue. Blood flow to different parts of the brain may be reduced by partial blockage or completely blocked by a blood clot. Currently, there is no permanent cure for Vascular Dementia or even a way to reverse the damage that already happened. But, Vascular Dementia treatment can help prevent further damage to the brain in affected people with Vascular Dementia and may slow down its progression. The primary prevention of VaD treatment aims to reduce the symptoms of the disease by eliminating its cause or main risk factors for Vascular Dementia. It constitutes prescribed drugs such as anti-dementia, anti-hypertensives, anticoagulants, vasodilator, anti-diabetics, antipsychotics, and other classes of drugs by which the progression of Vascular Dementia can be controlled. Secondary prevention may include management of stroke and prevention, by early diagnosis and appropriate treatment, medicines, such as cholinesterase inhibitors to treat Vascular Dementia symptoms, antidepressants to help with depression or other symptoms. Vasodilator drugs mainly work to prevent constriction of the blood vessels, Aspirin is a popular antiplatelet drug, NMDA antagonists, Memantine and Nicardipine, also showed improvement in cognitive deterioration. The current Vascular Dementia pipeline consists few products, which are in the initial, mid, and late phases of clinical development. The absence of any approved therapy specifically for Vascular Dementia is a severe unmet need. Consequently, it necessitated the development of new entities. Also, as the patient population is critically growing there is an urgent need for further research on the clinical effectiveness of pharmacologic management of Vascular Dementia. To combat these urgent needs key Vascular Dementia companies are developing novel drugs which are under clinical studies such as BAC (also called CSTC1, CHARSIRE Trauma Complex 1), a component of soybean extraction developed by Charsire Biotechnology Corp, is under investigation to treat a variety of diseases, including Alzheimer's disease and Vascular Dementia. PNA1, a rationally-designed Angiotensin-(1-7) Mas receptor agonist is being developed by a neuroinflammation company ProNeurogen for Vascular Dementia treatment. Resverlogix's Apabetalone is an entirely new epigenetic therapeutic, taken orally to improve the condition of people suffering from vascular diseases by lowering the expression of disease-related genes. Discover more about therapy set to grab substantial Vascular Dementia market share at Vascular Dementia Market Landscape  Vascular Dementia Pipeline Therapies and Key Companies BAC: Charsire Biotechnology Corp CY6463: Cyclerion Therapeutics As the companies are showing interest in developing drugs for treatment, the Vascular Dementia market is supposed to experience immense growth in the future. An increasing number of populations at high risk of Vascular Dementia such as geriatrics and smokers, as well as increasing understanding of diagnosis modalities, will boost the Vascular Dementia market in the coming years. In addition to that, increasing focus to develop Vascular Dementia treatment for the underlying disease and the absence of any FDA-approved drug serve as major Vascular Dementia market growth aspects. Along with these, the expected launch of emerging therapies will significantly impact the Vascular Dementia treatment market in the forecast period. On the other hand, factors such as clinical challenges in the management of disease, patients oblivious to early symptoms of Vascular Dementia, underdiagnosis of the disease, insufficient knowledge of diseases pathogenesis serve as an obstruction for the Vascular Dementia market opportunities. DelveInsight's, "Alzheimer's Disease (AD) Pipeline Insights, 2022," report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer's Disease (AD) pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key Alzheimer's Disease companies such as Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, and many others. DelveInsight's "Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Alzheimer's Disease, historical and forecasted epidemiology as well as the Alzheimer's disease market trends, market drivers and barriers, and key Alzheimer's Disease companies such as AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and many others, DelveInsight's 'Epilepsy - Market Insights, Epidemiology and Market Forecast– 2030' report offers rich insights into epidemiology, current and marketed treatments, growth prospects, and key Epilepsy companies including Neurelis, Biocodex, Aquestive Therapeutics, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Lundbeck, Greenwich Biosciences, Eisai Pharmaceuticals, Janssen Pharmaceuticals, Eisai, Zogenix, UCB, SK Life Science, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, Supernus Pharmaceuticals, Lundbeck, Pfizer, and many others. DelveInsight's "Frontotemporal Dementia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Frontotemporal Dementia, historical and forecasted epidemiology as well as the Frontotemporal Dementia market trends, market drivers and barriers, and key Frontotemporal Dementia companies such as TauRx Therapeutics Ltd, Alector, Axon Neuroscience, Passage Bio, Wave Life Sciences, Prevail Therapeutics, ProMIS Neurosciences, and others. DelveInsight's, "Frontotemporal Dementia Pipeline Insight, 2022," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Frontotemporal Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, and key Frontotemporal Dementia companies such as Alector, Prevail Therapeutics, Passage Bio, Inc., TauRx Pharmaceuticals, Wave Life Sciences Ltd., CAMP4 Therapeutics, Coya Therapeutics, SOLA Biosciences, and many others. DelveInsight's, "Dementia with Diabetes Pipeline Insights, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Dementia with Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical, non-clinical stage products, and key Dementia with Diabetes companies such as vTv Therapeutics, and others. Browse Through Our Blog Posts

Alector Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Alector Rank

  • When was Alector founded?

    Alector was founded in 2013.

  • Where is Alector's headquarters?

    Alector's headquarters is located at 131 Oyster Blvd, South San Francisco.

  • What is Alector's latest funding round?

    Alector's latest funding round is IPO.

  • How much did Alector raise?

    Alector raised a total of $194.5M.

  • Who are the investors of Alector?

    Investors of Alector include OrbiMed Advisors, Polaris Partners, Mission Bay Capital, Google Ventures, MRL Ventures and 19 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.